A Single Mutation in the “DSL” Motif of the Acyl Carrier Protein Can Prevent Its <i>In Vivo</i> Phosphopantetheinylation by <i>E. coli</i> Holo-Acyl Carrier Protein Synthase (AcpS)

The <i>Escherichia coli</i> expression system is the method of choice to obtain high yields of a pure protein. Since most biological pathways are evolutionarily conserved from bacteria to mammals, there is always a chance that a non-native protein shares sequence or structural homology with the natural substrate of an <i>E. coli</i> enzyme. In such cases, when this foreign protein is overexpressed in <i>E. coli</i>, it may be processed as a substrate by that enzyme, resulting in its modification. A notable example is the heterologous expression of Type II acyl carrier proteins (ACPs) in <i>E. coli</i>. Due to the conservation of a type II fatty acid synthesis pathway (FAS) across bacteria to mammals, the non-native type II ACPs are often recognized as a substrate by the <i>E. coli</i> 4'-phosphopantetheinyl transferase, also known as the Holo-acyl carrier protein synthase (AcpS). This undesirable modification is a concern when the objective is to obtain milligram amounts of apo-ACP. Here, using an approach combining mutagenesis, enzyme activity, and NMR, we have probed for the <i>E. coli</i> ACP (AcpP) residues that can prevent this <i>in vivo</i> modification. Taking cues from the AcpP-AcpS crystal structure (PDB entry 1F80), five charge-neutralization mutations were designed on the AcpP surface, i.e., D35N, E41A, E47A, E48A, and E47A/E48A, to disrupt the AcpP-AcpS interaction. All the AcpP mutants except D35N expressed as partially phosphopantetheinylated proteins in <i>E. coli</i>, presenting D35N mutagenesis as an attractive approach to prevent undesired modification of AcpP <i>in vivo.</i> The strategy was tested on two other non-native type II ACPs that express predominantly as phosphopantetheinylated proteins in <i>E. coli</i>, <i>Mus musculus</i> mitochondrial FAS ACP (mACP), and <i>Salmonella</i> Typhimurium invasion acyl carrier protein (IacP). A single D35N mutation in the "DSL" motif of these ACPs prevented their <i>in vivo</i> phosphopantetheinylation by AcpS, demonstrating D35N mutagenesis as a viable strategy to express apo-ACP in <i>E. coli</i>.

Authors

Institutions

Publication Details

Journal
Biochemistry
Published
2025-09-03
DOI
https://doi.org/10.1021/acs.biochem.4c00822
Primary Topic
Biochemical and Molecular Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Single Mutation in the “DSL” Motif of the Acyl Carrier Protein Can Prevent Its In Vivo Phosphopantetheinylation by E. coli Holo-Acyl Carrier Protein Synthase (AcpS)

S. S. Vaish, Monica Sundd, Rashima Prem, Chetna Dhembla et al.
Biochemistry
Biochemical and Molecular Research
article

A Single Mutation in the “DSL” Motif of the Acyl Carrier Protein Can Prevent Its In Vivo Phosphopantetheinylation by E. coli Holo-Acyl Carrier Protein Synthase (AcpS)

S. S. Vaish, Monica Sundd, Rashima Prem, Chetna Dhembla, Suman Kundu, Shalini Verma, Debodyuti Sadhukhan
article en

Abstract

The <i>Escherichia coli</i> expression system is the method of choice to obtain high yields of a pure protein. Since most biological pathways are evolutionarily conserved from bacteria to mammals, there is always a chance that a non-native protein shares sequence or structural homology with the natural substrate of an <i>E. coli</i> enzyme. In such cases, when this foreign protein is overexpressed in <i>E. coli</i>, it may be processed as a substrate by that enzyme, resulting in its modification. A notable example is the heterologous expression of Type II acyl carrier proteins (ACPs) in <i>E. coli</i>. Due to the conservation of a type II fatty acid synthesis pathway (FAS) across bacteria to mammals, the non-native type II ACPs are often recognized as a substrate by the <i>E. coli</i> 4'-phosphopantetheinyl transferase, also known as the Holo-acyl carrier protein synthase (AcpS). This undesirable modification is a concern when the objective is to obtain milligram amounts of apo-ACP. Here, using an approach combining mutagenesis, enzyme activity, and NMR, we have probed for the <i>E. coli</i> ACP (AcpP) residues that can prevent this <i>in vivo</i> modification. Taking cues from the AcpP-AcpS crystal structure (PDB entry 1F80), five charge-neutralization mutations were designed on the AcpP surface, i.e., D35N, E41A, E47A, E48A, and E47A/E48A, to disrupt the AcpP-AcpS interaction. All the AcpP mutants except D35N expressed as partially phosphopantetheinylated proteins in <i>E. coli</i>, presenting D35N mutagenesis as an attractive approach to prevent undesired modification of AcpP <i>in vivo.</i> The strategy was tested on two other non-native type II ACPs that express predominantly as phosphopantetheinylated proteins in <i>E. coli</i>, <i>Mus musculus</i> mitochondrial FAS ACP (mACP), and <i>Salmonella</i> Typhimurium invasion acyl carrier protein (IacP). A single D35N mutation in the "DSL" motif of these ACPs prevented their <i>in vivo</i> phosphopantetheinylation by AcpS, demonstrating D35N mutagenesis as a viable strategy to express apo-ACP in <i>E. coli</i>.

BiochemistryVol. 64(18)
University of Delhi (IN), National Institute of Immunology (IN)
Department of Biotechnology, Ministry of Science and Technology, India
Openalex Percentile: Top 79%
Biochemical and Molecular Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.